Yanxin Pei, Robert J. Wechsler-Reya  Cancer Cell 

Slides:



Advertisements
Similar presentations
Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr
Advertisements

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.
Fate Restriction and Multipotency in Retinal Stem Cells Lázaro Centanin, Burkhard Hoeckendorf, Joachim Wittbrodt Cell Stem Cell Volume 9, Issue 6, Pages.
Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung Zvi Granot, Erik Henke, Elizabeth A. Comen, Tari A. King, Larry Norton, Robert Benezra.
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.
Chemotherapy and Cancer Stem Cells
Illuminating the Properties of Prostate Luminal Progenitors
Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma  Fred C. Lam, Michael B. Yaffe  Cancer.
Of Brains and Blood: Developmental Origins of Glioma Diversity?
Ras Brakes for Hippo Developmental Cell
Charles Swanton, Julian Downward  Cancer Cell 
Accelerating drug discovery: Open source cancer cell biology?
mTOR Signaling in Melanoma: Oncogene-Induced Pseudo-Senescence?
Glioma Development: Where Did It All Go Wrong?
RAS unplugged: Negative feedback and oncogene-induced senescence
Andrew G. Muntean, Jay L. Hess  Cancer Cell 
Annapoorni Rangarajan, Sue J. Hong, Annie Gifford, Robert A. Weinberg 
MDS Is a Stem Cell Disorder After All
Deregulating EMT and Senescence: Double Impact by a Single Twist
Volume 26, Issue 1, Pages 1-2 (July 2014)
Wild-Type p53: Tumors Can't Stand It
A Radical Role for p38 MAPK in Tumor Initiation
Pontine Infantile Glioma Simplified
The AML Salad Bowl Cancer Cell
Cécile L. Maire, Keith L. Ligon  Cancer Cell 
Fibrinogen in the Nervous System: Glia Beware
Imported Stem Cells Strike against Stroke
Gliomas “Dope Up” for Growth
Of Brains and Blood: Developmental Origins of Glioma Diversity?
Da Yong Lee, Scott M. Gianino, David H. Gutmann  Cancer Cell 
The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?
Raf-1 and Squamous Cell Carcinoma: Rok-ing the Boat
Volume 18, Issue 2, Pages (February 2016)
Giulio Francia, Urban Emmenegger, Robert S. Kerbel  Cancer Cell 
Rushika M. Perera, Nabeel Bardeesy  Cancer Cell 
A New “Brew” of MALT1 Inhibitors
Deregulating EMT and Senescence: Double Impact by a Single Twist
Theodoros Karantanos, Timothy C. Thompson  Cancer Cell 
The RAF Inhibitor Paradox Revisited
An Integrin-Linked Machinery of Cytoskeletal Regulation that Enables Experimental Tumor Initiation and Metastatic Colonization  Tsukasa Shibue, Mary W.
RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion
BMPing Off Glioma Stem Cells
Bmi1 and Cell of Origin Determinants of Brain Tumor Phenotype
Hit 'Em Where They Live: Targeting the Cancer Stem Cell Niche
NO Signals from the Cancer Stem Cell Niche
Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
A common pathway for genetic events leading to pheochromocytoma
Activation of B-raf in Non-Malignant Nevi Predicts a Novel Tumor Suppressor Gene in Melanoma (MAP Kinase Phosphatase)  Jack L. Arbiser  Journal of Investigative.
Tailor Made Protein Synthesis for HSCs
To Infinium, and Beyond! Cancer Cell
Volume 10, Issue 3, Pages (September 2006)
All Roads Lead to the Ribosome
Regulation of Angiogenesis and Tumorigenesis by Signal Transduction Cascades: Lessons from Benign and Malignant Endothelial Tumors  Robert Klafter, Jack.
Tracy-Ann Read, Robert J. Wechsler-Reya  Cancer Cell 
Attacking Cancer at Its Root
Searching for leukemia stem cells—Not yet the end of the road?
There's a Time and a Place for MYCN
c-Raf in KRas Mutant Cancers: A Moving Target
Is Cyclin D1-CDK4 kinase a bona fide cancer target?
Santosh Kesari, Charles D. Stiles  Neuron 
Ibrutinib Treatment of CLL: The Cancer Fights Back
Pharmacological Rescue of p53 in Cancer Therapy: Widening the Sensitive Tumor Spectrum by Targeting MDMX  Jean-Christophe Marine  Cancer Cell  Volume.
Mind the IQGAP Cancer Cell
Anthony N. Imbalzano, Stephen N. Jones  Cancer Cell 
The AML Salad Bowl Cancer Cell
Turning Reciprocal Feedback Regulation into Combination Therapy
Ras Brakes for Hippo Developmental Cell
Presentation transcript:

A Malignant Oligarchy: Progenitors Govern the Behavior of Oligodendrogliomas  Yanxin Pei, Robert J. Wechsler-Reya  Cancer Cell  Volume 18, Issue 6, Pages 546-547 (December 2010) DOI: 10.1016/j.ccr.2010.11.031 Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 1 Cell of Origin and Oncogenic Mutations Collaborate to Determine Glioma Behavior Activation of growth factor (EGF, PDGF) or Ras-MAP kinase (H-Ras, B-raf, NF-1) signaling pathways in neural stem cells (NSCs) or progenitors usually results in hyperplasia or low-grade gliomas; mutations in tumor suppressors (p53, PTEN, Ink4a/Arf) convert these to high-grade tumors. When genetic lesions are targeted to NSCs or astrocyte progenitors (APCs), the resulting tumors (astrocytomas) retain stem cell characteristics: multipotency, neurosphere formation, and resistance to therapy. When mutations are initiated in oligodendrocyte progenitors (OPCs), the resulting tumors (oligodendrogliomas) have characteristics of OPCs, including restricted differentiation, poor neurosphere formation and sensitivity to therapy. (Illustration by Jill Gregory.) Cancer Cell 2010 18, 546-547DOI: (10.1016/j.ccr.2010.11.031) Copyright © 2010 Elsevier Inc. Terms and Conditions